Form 8-K Vaxart, Inc. For: Jun 06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 6, 2023
(Exact name of registrant as specified in its charter)
|
|
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
||
|
|
|||
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (650 ) 550-3500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01
|
Other Events.
|
On June 6, 2023, Vaxart, Inc. issued a press release providing an update on its norovirus vaccine candidate. A copy of the press release is filed as Exhibit 99.1 hereto and, other than the quotes by Dr. James F. Cummings, is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
Exhibit
|
Description
|
|
99.1 | Press Release, dated June 6, 2023. | |
104
|
Cover Page Interactive Data File (embedded within Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Vaxart, Inc.
|
|||||||
Dated: June 6, 2023
|
|||||||
By:
|
/s/ ANDREI FLOROIU
|
||||||
Andrei Floroiu
|
|||||||
President and Chief Executive Officer
|
ATTACHMENTS / EXHIBITS
EXHIBIT 99.1_NOROVIRUS VACCINE UPDATE PR
XBRL TAXONOMY EXTENSION SCHEMA
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
XBRL TAXONOMY EXTENSION LABEL LINKBASE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agents Win Again! Epique Realty Amazes with Incredible Last Benefit Reveal at PowerCON: Delta Dental and Vision
- Australian Oilseeds, Largest APAC Producer of Non-Chemical, Non-GMO “Cold-Processing” Vegetable Oil, Enters into Contract with Woolworths and Costco Australia.
- Intuitive Announces Board of Directors Elections and Retirements
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!